Contact
searchSearch
HMP Global
Login
Sameera Kumar, MD
Conference Coverage
Radiation for Patients With Stage 3 Non-Small Cell Lung Cancer
03/27/2025
Sameera Kumar, MD, highlights the role radiation plays in the treatment of patients with stage 3 non-small cell lung cancer.
Sameera Kumar, MD, highlights the role radiation plays in the treatment of patients with stage 3 non-small cell lung cancer.
Sameera Kumar, MD, highlights...
03/27/2025
Oncology
William Grady, MD
Conference Coverage
Biomarker-Based Testing vs Colonoscopy for Colorectal Cancer Screening
03/27/2025
William Grady, MD, compares biomarker-based testing and colonoscopy when considering options for colorectal cancer screening.
William Grady, MD, compares biomarker-based testing and colonoscopy when considering options for colorectal cancer screening.
William Grady, MD, compares...
03/27/2025
Oncology
Estelamari Rodriguez, MD, MPH
Conference Coverage
First-Line CTLA-4 Inhibitors for Patients With Non-Small Cell Lung Cancer
03/27/2025
Estelamari Rodriguez, MD, MPH, assesses the potential of CTLA-4 inhibitors in the first-line setting for patients with non-small cell lung cancer.
Estelamari Rodriguez, MD, MPH, assesses the potential of CTLA-4 inhibitors in the first-line setting for patients with non-small cell lung cancer.
Estelamari Rodriguez, MD, MPH,...
03/27/2025
Oncology
Deborah Doroshow, MD, PhD
Conference Coverage
Immunotherapy for Patients With Small Cell Lung Cancer
03/27/2025
Deborah Doroshow, MD, PhD, discusses the role of immunotherapy when treating patients with small cell lung cancer.
Deborah Doroshow, MD, PhD, discusses the role of immunotherapy when treating patients with small cell lung cancer.
Deborah Doroshow, MD, PhD,...
03/27/2025
Oncology
Reid Ness, MD, MPH
Conference Coverage
Assessing Evidence for Colonoscopy as a Primary Screening Tool
03/27/2025
Reid Ness, MD, MPH, discusses the nordICC trial, which assessed the efficacy of using colonoscopy as a primary screening tool.
Reid Ness, MD, MPH, discusses the nordICC trial, which assessed the efficacy of using colonoscopy as a primary screening tool.
Reid Ness, MD, MPH, discusses...
03/27/2025
Oncology
Vivek Subbiah, MD
Conference Coverage
Tumor Agnostic Therapies for Patients With Solid Tumors
03/27/2025
Vivek Subbiah, MD, discusses advances in tumor agnostic therapies and explores how these therapies can shift the treatment landscape for patients with solid tumors.
Vivek Subbiah, MD, discusses advances in tumor agnostic therapies and explores how these therapies can shift the treatment landscape for patients with solid tumors.
Vivek Subbiah, MD, discusses...
03/27/2025
Oncology
Reid Ness, MD, MPH
Conference Coverage
Colonoscopy for the Detection of Colorectal Cancer
03/27/2025
Reid Ness, MD, MPH, argues that colonoscopy is superior compared to biomarker-based testing for the detection of colorectal cancer.
Reid Ness, MD, MPH, argues that colonoscopy is superior compared to biomarker-based testing for the detection of colorectal cancer.
Reid Ness, MD, MPH, argues that...
03/27/2025
Oncology
Shipra Gandhi, MD, Winship Cancer Institute
Videos
An Argument Against Earlier Novel Endocrine Backbones for Breast Cancer
03/27/2025
Shipra Gandhi, MD, makes the case against moving novel endocrine backbones to earlier lines of therapy in breast cancer.
Shipra Gandhi, MD, makes the case against moving novel endocrine backbones to earlier lines of therapy in breast cancer.
Shipra Gandhi, MD, makes the...
03/27/2025
Oncology
Raghav Sundar, MD, PhD, Yale Cancer Center
Videos
Integrating Anatomy Into Treatment Decisions for Gastrointestinal Cancers
03/27/2025
Raghav Sundar, MD, PhD, discusses the importance of considering tumor biology and anatomic site when determining treatments for patients with gastrointestinal cancers.
Raghav Sundar, MD, PhD, discusses the importance of considering tumor biology and anatomic site when determining treatments for patients with gastrointestinal cancers.
Raghav Sundar, MD, PhD,...
03/27/2025
Oncology
Seth Wander, MD, PhD
Conference Coverage
Earlier Use of Novel Endocrine Backbones for Patients With HR-Positive Breast Cancer
03/26/2025
Seth Wander, MD, PhD, discusses key considerations for moving novel endocrine backbones into earlier lines of therapy for patients with hormone receptor-positive breast cancer.
Seth Wander, MD, PhD, discusses key considerations for moving novel endocrine backbones into earlier lines of therapy for patients with hormone receptor-positive breast cancer.
Seth Wander, MD, PhD, discusses...
03/26/2025
Oncology
Christian Rolfo, MD, PhD
Conference Coverage
Role of Upfront Liquid Biopsies in the Diagnosis of Lung Cancer
03/26/2025
Christian Rolfo, MD, explores the evidence supporting the use of upfront liquid biopsies in the diagnosis of lung cancer.
Christian Rolfo, MD, explores the evidence supporting the use of upfront liquid biopsies in the diagnosis of lung cancer.
Christian Rolfo, MD, explores...
03/26/2025
Oncology
Richard Finn, MD
Conference Coverage
Dual Checkpoint Inhibition for Patients With Advanced Hepatocellular Carcinoma
03/25/2025
Richard Finn, MD, assesses the use of dual checkpoint inhibition in the first-line setting for patients with advanced hepatocellular carcinoma.
Richard Finn, MD, assesses the use of dual checkpoint inhibition in the first-line setting for patients with advanced hepatocellular carcinoma.
Richard Finn, MD, assesses the...
03/25/2025
Oncology
James Harding, MD
Conference Coverage
Combination VEGF and Immune Checkpoint Inhibitors as a First-Line Option for Patients With Advanced Hepatocellular Carcinoma
03/25/2025
James Harding, MD, discusses advantages associated with combining VEGF inhibitors and immune checkpoint inhibition in the first-line setting for patients with advanced hepatocellular carcinoma.
James Harding, MD, discusses advantages associated with combining VEGF inhibitors and immune checkpoint inhibition in the first-line setting for patients with advanced hepatocellular carcinoma.
James Harding, MD, discusses...
03/25/2025
Oncology
Kelly McCann, Md, PhD, University of California, Los Angeles
Videos
Sequential Use of Antibody-Drug Conjugates for Patients With Breast Cancer
03/25/2025
Kelly McCann, MD, PhD, University of California, Los Angeles, discusses the debate over whether to use antibody-drug conjugates sequentially for patients with breast cancer. Dr McCann discusses the potential for cross-resistance with these...
Kelly McCann, MD, PhD, University of California, Los Angeles, discusses the debate over whether to use antibody-drug conjugates sequentially for patients with breast cancer. Dr McCann discusses the potential for cross-resistance with these...
Kelly McCann, MD, PhD,...
03/25/2025
Oncology
Heather Moore, PharmD, BCOP, CPP, Duke Cancer Center
Videos
Managing Adverse Events in Breast Cancer Treatment
03/25/2025
Heather Moore, PharmD, BCOP, CPP, discusses management of adverse events when treating patients with breast cancer.
Heather Moore, PharmD, BCOP, CPP, discusses management of adverse events when treating patients with breast cancer.
Heather Moore, PharmD, BCOP,...
03/25/2025
Oncology
Jamie Chaft, MD
Conference Coverage
Surgery vs Radiation for Patients With Stage 3 Non-Small Cell Lung Cancer
03/25/2025
Jamie Chaft, MD, highlights the role of surgical resection in the treatment of patients with stage 3 non-small cell lung cancer.
Jamie Chaft, MD, highlights the role of surgical resection in the treatment of patients with stage 3 non-small cell lung cancer.
Jamie Chaft, MD, highlights the...
03/25/2025
Oncology
Don Dizon, MD
Conference Coverage
Impact of Anticancer Treatment on Sexual Function and Intimacy
03/22/2025
Don Dizon, MD, explores the relationship between anticancer treatment-related sexual side effects and intimacy among patients undergoing cancer treatment.
Don Dizon, MD, explores the relationship between anticancer treatment-related sexual side effects and intimacy among patients undergoing cancer treatment.
Don Dizon, MD, explores the...
03/22/2025
Oncology
News
HMP Global’s Great Debates in Solid Tumors events deliver best of three popular oncology conferences
03/19/2025
The best of HMP Global’s three Great Debates programs will be featured in one 2025 series, Great Debates in Solid Tumors, delivering a more comprehensive learning experience for oncology clinicians in the gastrointestinal, women’s and lung...
The best of HMP Global’s three Great Debates programs will be featured in one 2025 series, Great Debates in Solid Tumors, delivering a more comprehensive learning experience for oncology clinicians in the gastrointestinal, women’s and lung...
The best of HMP Global’s three...
03/19/2025
Oncology

About

About

Join us for the first-ever Great Debates in Solid Tumors, where three established oncology programs come together in one comprehensive event.

This unique event offers exclusive access to a distinguished faculty presenting the latest clinical data and evolving standards across the following treatment areas: gastrointestinal, women’s, and lung cancers. Engage in rigorous debates and case-based discussions, designed to deepen your understanding of evidence-based approaches, while networking with colleagues equally committed to advancing patient outcomes. Don’t miss this opportunity to connect, learn, and lead in solid tumor care.
 

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use